PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical

Schlieren / Zurich, Switzerland, September 18, 2018 / B3C newswire / — Neurimmune today announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a collaboration focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform. The milestone triggers a pre-agreed milestone payment to Neurimmune.

“We highly appreciate a key success in drug discovery of human-derived monoclonal antibodies with Neurimmune’s proprietary platform.”, said Hiromu Habashita, Ph.D., Corporate Officer and Executive Director, Discovery and Research of Ono. “We believe this progress will lead to the delivery of a novel and innovative treatment for patients with neurodegenerative diseases.”

“We highly value the collaborative nature of our partnership with Ono, a global pioneer of innovative medicines.”, said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “We are excited about the rapid progress within the first year of this collaboration and look forward to advance novel human-derived antibody candidates for CNS indications of high unmet medical need.”

Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC